ELOVL2 Genotype

Two people can eat the same amount of fish or flaxseed and end up with very different omega-3 levels in their blood. A meaningful chunk of that difference is written into your DNA, and one of the genes doing the writing is ELOVL2 (elongation of very long chain fatty acids 2).

This test reads the version of ELOVL2 you inherited at birth. The result tells you how efficiently your body completes the final elongation steps that feed into the long-chain omega-3 fats (especially DHA) that your brain, heart, and eyes rely on. It does not change over your lifetime, so you only need to do it once.

What ELOVL2 Actually Does

ELOVL2 codes for an enzyme called an elongase, which adds carbon atoms to fatty acids two at a time. Earlier steps in the omega-3 pathway, handled by other enzymes (FADS1, FADS2, and ELOVL5), turn plant-based ALA into EPA. ELOVL2's specific job is the final stretch: it elongates EPA to DPA (docosapentaenoic acid), and DPA to a 24-carbon precursor that another enzyme (FADS2) then desaturates so the cell can finish making DHA (docosahexaenoic acid). In other words, EPA is a substrate that ELOVL2 acts on, and DHA is a downstream product that depends on ELOVL2 doing its part of the chain.

In a study of 8,866 adults of European ancestry, certain minor-allele variants in ELOVL2 were tied to higher EPA and DPA but lower DHA in blood, which fits a pattern of slower elongation at the final step. A review of the same pathway noted that carriers of a three-variant ELOVL2 haplotype have lower DHA, the form your brain depends on most.

Why This Genotype Matters for Omega-3 Status

The clearest practical finding is how ELOVL2 changes your response to fish oil. In an 86-person study of healthy adults taking fish oil for four weeks, carriers of one or two copies of the minor allele at a variant called rs953413 ended up with significantly higher EPA, DPA, DHA, and Omega-3 Index than people with the common version. In plain terms, the same supplement produced a bigger payoff for some people than others, and the genotype helped predict which.

A separate exploratory study found the effect of rs953413 on DHA response to EPA supplementation was sex-dependent: females with the AA genotype had a larger plasma DHA increase, while males with the same genotype showed a decrease. So the same variant can play out differently depending on sex, and that nuance is worth keeping in mind when reading any single-cohort result.

A separate study of pregnant women in China found that ELOVL2 variants shaped the omega-3 and omega-6 content of breast milk, and that mothers with certain haplotypes who also ate more DHA had higher levels of linoleic acid, arachidonic acid, EPA, and DHA in their milk. The gene and the diet work together.

Body Weight and Insulin Resistance

In 1,649 children with obesity studied in Italy, the minor allele of an ELOVL2 variant called rs2236212 was linked to higher BMI z-score and reduced estimated elongase activity. The variant did not change standard cholesterol or insulin-resistance scores in that study, but it shifted the underlying fat-building machinery.

In a Mexican adult cohort of 1,075 people, ELOVL2 variants were tied to insulin-resistance markers and total cholesterol, with sex-specific patterns: some associations (like links to insulin-resistance markers) appeared mainly in men, while the rs2281591 variant was associated with lower odds of high waist circumference specifically in women. Smaller studies in Brazilian and Italian populations also reported links to lipid markers, suggesting that age, sex, and ancestry all change how the genotype shows up in the body.

Neurodevelopment

Several ELOVL2 variants have been studied in relation to autism spectrum disorder. In 486 Chinese children, variants rs17606561, rs3756963, and rs9468304 were linked to higher risk under specific inheritance patterns, while rs10498676 was linked to lower risk. The proposed mechanism is altered DHA synthesis during early brain development. The effect sizes are modest and have not been replicated across all populations, so this is a research-stage finding rather than a clinical screening tool.

Cancer Prognosis

A study of 1,267 melanoma patients identified an ELOVL2 variant, rs3734398, where the C allele was tied to better melanoma-specific survival, with a hazard ratio of 0.66 (meaning carriers were about a third less likely to die from melanoma during follow-up than non-carriers). The same variant was linked to higher ELOVL2 gene expression. This is an interesting prognostic signal but does not mean ELOVL2 genotype is a screening test for melanoma.

The Counterintuitive Finding

In a separate analysis of 5,795 adults, common variants in fatty-acid elongase genes were not associated with myocardial infarction risk or with standard cholesterol and inflammation markers. ELOVL2 genotype clearly shifts your blood fatty-acid profile, but the downstream link to actual cardiovascular events is mixed. The cleanest way to think about this: ELOVL2 helps explain how your body handles omega-3 raw materials, but it is one input among many that determine heart attack risk, and it should not be read as a standalone cardiovascular risk score.

Why a One-Time Test Still Drives Ongoing Decisions

Your ELOVL2 genotype does not change with age, diet, or supplementation, so there is no reason to retest it. The value of the result is what you do with it over years.

If you are a minor-allele carrier, a useful companion test is the Omega-3 Index, which measures the actual EPA and DHA content of your red blood cells. The fish-oil response study showed that genotype predicted who would benefit most from supplementation, which means the Omega-3 Index is the marker to track when you change your dose or switch from plant-based to marine omega-3 sources. Pairing genotype with the Omega-3 Index is a clinical-judgment recommendation, not a guideline-endorsed protocol. Retest the Omega-3 Index 3 to 4 months after any change, then annually.

What to Do With an At-Risk Genotype

If your result shows you carry a variant associated with slower elongation (lower DHA in blood), the practical next step is not to treat ELOVL2 itself, which you cannot. Instead, order a few companion tests so you can see how the genotype is actually expressing in your body: an Omega-3 Index for current EPA and DHA status, a standard lipid panel and ApoB for cardiovascular context, fasting insulin and HbA1c if you have any metabolic risk factors, and consider sharing the result with biological siblings and children, who have meaningful odds of carrying the same variant.

Carrying a variant does not mean you will develop any of the conditions associated with it. ELOVL2 variants shift averages across large populations; individual outcomes depend on diet, body weight, exercise, other genetic factors, and luck. Use the result as a reason to monitor more carefully, not as a diagnosis.

When Results Can Be Misleading

Genetic tests have their own confounders that differ from blood biomarker tests:

• Variant panel coverage: this test detects the specific ELOVL2 variants on its panel. A result showing no risk variants does not rule out rarer variants in the same gene that the assay was not designed to find.
• Ancestry effects: many ELOVL2 associations were first found in European, Chinese, or Mexican cohorts. Allele frequencies and downstream effects differ by ancestry, so a variant that raised risk in one population may have a different effect in another.
• Confusion with ELOVL2 methylation: ELOVL2 is also one of the most-studied epigenetic clocks, where methylation of the gene rises steadily with age. Methylation is a separate measurement that changes over your lifetime; it is not what this genotype test reports.
• Direct-to-consumer reports: 23andMe and similar services may report some ELOVL2 variants but use different chips and different quality standards than clinical-grade testing. Treat consumer reports as a starting point, not a final answer.

How This Fits the Bigger Picture

ELOVL2 genotype is a research-leaning test. It does not replace standard lipid panels, the Omega-3 Index, or metabolic testing. What it adds is context: when your Omega-3 Index is low despite eating fish, or when fish oil supplements seem to do less for you than for a partner taking the same dose, this gene is one place to look. Pair it with the phenotype tests that actually measure what is in your blood today, and use both together to make decisions about diet, supplementation, and how aggressively to monitor your cardiometabolic markers over time.